A 62-year-old male smoker with COPD GOLD stage 3 (FEV₁ 35% predicted) and chronic bronchitis presents for routine follow-up. He is currently on tiotropium and salbutamol as needed. Regarding pharmacological management of stable COPD, all of the following statements are correct EXCEPT:

Explanation

## Correct Answer Analysis **Key Point:** Theophylline is NOT first-line in COPD management. It is a second- or third-line agent reserved for specific situations due to narrow therapeutic index and drug interactions. ## COPD Pharmacotherapy Hierarchy | Agent Class | Role in COPD | Evidence Level | |---|---|---| | Long-acting anticholinergics (LAMA) | First-line for stable COPD | High | | Long-acting beta-2 agonists (LABA) | First-line; reduce exacerbations | High | | Inhaled corticosteroids (ICS) | Add if exacerbation history; ICS+LABA or ICS+LABA+LAMA | High | | Phosphodiesterase-4 inhibitors (e.g., roflumilast) | Adjunct in chronic bronchitis with frequent exacerbations | Moderate | | Theophylline | Second/third-line; narrow therapeutic window | Low | ## Why Each Statement Is Correct (Except #4) **Statement 1 (LABA reduce mortality):** LABAs in combination with ICS reduce exacerbations and mortality risk in COPD. When used as monotherapy, LABA alone does not reduce mortality, but in the context of GOLD stage 3, combination therapy is standard. **Statement 2 (ICS in GOLD stage 3 with exacerbation history):** GOLD 2023 recommends ICS+LABA or ICS+LABA+LAMA in patients with exacerbation history, which is standard for this patient profile. **Statement 3 (Roflumilast in chronic bronchitis):** Roflumilast is a PDE-4 inhibitor approved for COPD with chronic bronchitis phenotype and recurrent exacerbations. It reduces exacerbation frequency by ~20%. **Statement 4 (Theophylline as first-line):** ~~Theophylline~~ is NOT first-line. First-line agents are LAMAs and LABAs. Theophylline has a narrow therapeutic index (10–20 μg/mL), significant drug interactions, and adverse effects (arrhythmias, tremor, nausea). It is reserved for resource-limited settings or as adjunctive therapy in severe disease. **High-Yield:** COPD pharmacotherapy follows a stepwise approach: LAMA or LABA monotherapy → LAMA+LABA → Add ICS if exacerbations → Consider roflumilast or azithromycin for frequent exacerbators. Theophylline is rarely used in modern practice. **Clinical Pearl:** In India, where theophylline was historically used, current NEET PG and INI-CET emphasize LAMA/LABA-based regimens aligned with GOLD guidelines. Theophylline should be recognized as outdated first-line therapy.